Genmab Management
Management criteria checks 4/4
We currently do not have sufficient information about the CEO.
Key information
Jan G.J. de Winkel
Chief executive officer
kr.44.3m
Total compensation
CEO salary percentage | 20.8% |
CEO tenure | 14yrs |
CEO ownership | 0.9% |
Management average tenure | 7.3yrs |
Board average tenure | 7.3yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Mar 31 2024 | n/a | n/a | kr.5b |
Dec 31 2023 | kr.44m | kr.9m | kr.4b |
Sep 30 2023 | n/a | n/a | kr.4b |
Jun 30 2023 | n/a | n/a | kr.5b |
Mar 31 2023 | n/a | n/a | kr.5b |
Dec 31 2022 | kr.42m | kr.9m | kr.5b |
Sep 30 2022 | n/a | n/a | kr.6b |
Jun 30 2022 | n/a | n/a | kr.4b |
Mar 31 2022 | n/a | n/a | kr.2b |
Dec 31 2021 | kr.38m | kr.8m | kr.3b |
Sep 30 2021 | n/a | n/a | kr.3b |
Jun 30 2021 | n/a | n/a | kr.3b |
Mar 31 2021 | n/a | n/a | kr.6b |
Dec 31 2020 | kr.37m | kr.7m | kr.5b |
Sep 30 2020 | n/a | n/a | kr.6b |
Jun 30 2020 | n/a | n/a | kr.6b |
Mar 31 2020 | n/a | n/a | kr.2b |
Dec 31 2019 | kr.35m | kr.7m | kr.2b |
Sep 30 2019 | n/a | n/a | kr.2b |
Jun 30 2019 | n/a | n/a | kr.1b |
Mar 31 2019 | n/a | n/a | kr.1b |
Dec 31 2018 | kr.28m | kr.7m | kr.1b |
Sep 30 2018 | n/a | n/a | kr.1b |
Jun 30 2018 | n/a | n/a | kr.1b |
Mar 31 2018 | n/a | n/a | kr.1b |
Dec 31 2017 | kr.27m | kr.7m | kr.1b |
Compensation vs Market: Jan G.J.'s total compensation ($USD6.44M) is about average for companies of similar size in the MX market ($USD5.98M).
Compensation vs Earnings: Jan G.J.'s compensation has been consistent with company performance over the past year.
CEO
Jan G.J. de Winkel (63 yo)
14yrs
Tenure
kr.44,300,000
Compensation
Dr. Jan G.J. van de Winkel, Ph.D. is Independent Director of HOOKIPA Pharma Inc. from 2023 and serves as Chairman of the Board since 2024. Dr. Winkel served as a Member of Advisory board at Thuja Capital M...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Co-Founder | 14yrs | kr.44.30m | 0.94% DKK 2.9b | |
Executive VP & CFO | 4.3yrs | kr.19.60m | 0.011% DKK 33.5m | |
Executive VP & COO | 4.3yrs | kr.21.80m | 0.0045% DKK 13.8m | |
Executive VP & Chief Legal Officer | 14.4yrs | kr.10.10m | no data | |
Executive VP & Chief People Officer | no data | kr.13.20m | no data | |
Executive VP & Chief Strategy Officer | 10.4yrs | kr.8.90m | no data | |
Senior Director of Clinical Operations & Non-Independent Director | no data | kr.800.00k | 0.00060% DKK 1.8m | |
Executive VP & Chief Development Officer | 7.3yrs | kr.21.70m | 0.014% DKK 41.8m | |
Executive VP | 3.3yrs | kr.19.80m | 0.0048% DKK 14.7m | |
Senior Director | no data | kr.1.10m | 0.00081% DKK 2.5m | |
Senior Director of Finance Japan & Non-Independent Director | no data | kr.800.00k | 0.00013% DKK 400.8k | |
Senior Director | no data | no data | no data |
7.3yrs
Average Tenure
51yo
Average Age
Experienced Management: GMAB N's management team is seasoned and experienced (7.3 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Senior Director of Clinical Operations & Non-Independent Director | 2.4yrs | kr.800.00k | 0.00060% DKK 1.8m | |
Senior Director | 5.3yrs | kr.1.10m | 0.00081% DKK 2.5m | |
Senior Director of Finance Japan & Non-Independent Director | 2.4yrs | kr.800.00k | 0.00013% DKK 400.8k | |
Non-Independent Director | 20.6yrs | kr.1.70m | 0.014% DKK 44.4m | |
Independent Director | 2.3yrs | kr.1.90m | no data | |
Independent Chairman of the Board | 7.3yrs | kr.2.80m | 0.0089% DKK 27.5m | |
Independent Director | 7.3yrs | kr.1.50m | 0.0052% DKK 16.1m | |
Independent Deputy Chairman | 9.4yrs | kr.2.10m | 0.0075% DKK 23.2m | |
Independent Director | 9.4yrs | kr.1.50m | 0.0032% DKK 10.0m |
7.3yrs
Average Tenure
59yo
Average Age
Experienced Board: GMAB N's board of directors are considered experienced (7.3 years average tenure).